08.25.16
Sibelius Limited has launched its first epigenetically active extract of sage available for commercial use, designed to enhance cognition. The U.K.-based natural products company, which develops natural ingredients with anti-aging epigenetic resetting capabilities, has developed this new sage extract using its patented Chronoscreen technology.
The Chronoscreen technology measures the effect natural ingredients have on the life span extension of whole organisms exposed to a treatment. Data on the sage extract show strong dose dependent epigenetic resetting capabilities in whole organisms, according to the company.
Sibelius CEO Peter Leyland considers this an important step forward for the company. “Up to now our clients have known us as a partner for testing their proprietary ingredients and products,” he said. “This product offers our clients something more, a reliable and effective ingredient with epigenetic resetting capabilities, backed by our expertise in botanicals and the science of epigenetics.”
Clinical trials of the sage extract have been conducted among a cohort of healthy seniors, and showed significant improvement compared to a baseline in secondary memory and attention accuracy. Subjects were given a single 333 mg dose and responses were measured over periods of between 1- 6 hours using a CDR computerized assessment.
The sage extract has been developed as a single ingredient product, and offers potential when combined with other extracts and ingredients to produce consumer products with a variety of different benefits. Manufacturers can work with Sibelius and its Chronoscreen technology to test the epigenetic activity of individual or combined ingredients, and confirm specific areas of efficacy using model organisms.
For more information: http://sibeliusnaturalproducts.com
The Chronoscreen technology measures the effect natural ingredients have on the life span extension of whole organisms exposed to a treatment. Data on the sage extract show strong dose dependent epigenetic resetting capabilities in whole organisms, according to the company.
Sibelius CEO Peter Leyland considers this an important step forward for the company. “Up to now our clients have known us as a partner for testing their proprietary ingredients and products,” he said. “This product offers our clients something more, a reliable and effective ingredient with epigenetic resetting capabilities, backed by our expertise in botanicals and the science of epigenetics.”
Clinical trials of the sage extract have been conducted among a cohort of healthy seniors, and showed significant improvement compared to a baseline in secondary memory and attention accuracy. Subjects were given a single 333 mg dose and responses were measured over periods of between 1- 6 hours using a CDR computerized assessment.
The sage extract has been developed as a single ingredient product, and offers potential when combined with other extracts and ingredients to produce consumer products with a variety of different benefits. Manufacturers can work with Sibelius and its Chronoscreen technology to test the epigenetic activity of individual or combined ingredients, and confirm specific areas of efficacy using model organisms.
For more information: http://sibeliusnaturalproducts.com
